Omaha, NENCT06801236Now EnrollingIRB Ready

Prostate Cancer (Adenocarcinoma) Clinical Trial in Omaha, NE

Access cutting-edge prostate cancer (adenocarcinoma) treatment through this clinical trial at a research site in Omaha. Study-provided care at no cost to qualified participants.

Sponsored by Acerand Therapeutics (Hong Kong) Limited

Quick Self-Assessment

See if you qualify for this Omaha location

Preparing your pre-screening questions…

Expert Care in Omaha

Access prostate cancer (adenocarcinoma) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer (adenocarcinoma) treatment provided free

Apply for This Omaha Location

Check if you qualify for this prostate cancer (adenocarcinoma) clinical trial in Omaha, NE

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Omaha

    Convenient for NE residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Omaha site if eligible
  4. 4Begin participation

About This Prostate Cancer (Adenocarcinoma) Study in Omaha

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).

Sponsor: Acerand Therapeutics (Hong Kong) Limited

Who Can Participate

Inclusion Criteria

Provide written informed consent
Metastatic Castration-resistant Prostate Cancer with ongoing androgen - deprivation therapy (ADT) or have bilateral orchiectomy
Difficult to treat or intolerant to standard treatment (post at least 1 line of NHA and taxane-based chemo in mHSPC or mCRPC), suitable for investigational treatment;
Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Has a life expectancy of at least 6 months
Adequate organ function and bone marrow function

Exclusion Criteria

Receiving any anti-cancer drugs or other treatment, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period;
Concomitant use of medications or herbal supplements known to be moderate to strong CYP3A4 inhibitors/inducers, or P-gp inhibitors, known to prolong the QT interval.
Any previous treatment-related toxicities have not recovered.
Spinal cord compression or known brain metastases or leptomeningeal carcinomatosis.
Severe cardiovascular disorders.
Known gastrointestinal (GI) disorder or GI procedure
History of gastric and duodenal perforation.
History of pituitary dysfunction.
Poorly controlled diabetes mellitus.
Active or uncontrolled autoimmune disease
Active infections, or a known history of HIV infection, or a known active hepatitis B or C, or a known active tuberculosis.
Other malignancies requiring treatment within 3 years prior to the first dose of study drug
Known allergy or hypersensitivity to any of the excipients of ACE-232.
Has other medical conditions that at the discretion of the investigator interfere with safety or efficacy evaluation, or treatment compliance.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Omaha?

Yes, this clinical trial (NCT06801236) has an active research site in Omaha, NE that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer (Adenocarcinoma) Treatment Options in Omaha, NE

If you're searching for prostate cancer (adenocarcinoma) treatment options in Omaha, NE, this clinical trial (NCT06801236) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Omaha research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer (adenocarcinoma) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer (adenocarcinoma) clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Omaha, NE

See all prostate cancer clinical trials recruiting in Omaha — not just this study.

Browse Prostate Cancer Trials in Omaha →

Browse More Trials by Condition

Prostate Cancer TrialsAlzheimers Disease TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Omaha?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Omaha, NE